GISSI: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


The '''Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico''' (GISSI) (Italian group for the study of the survival of Myocardial Infarction) is an influential [[cardiology]] research group founded as a collaboration between two Italian organisations – the Mario Negri Institute and the Associazione Nazionale dei Medici Cardiologi Ospedalieri (ANMCO).<ref name="GISSI">http://www.gissi.org/EngIntro/T_Intro_ENG.php</ref> The trials carried out by GISSI have "obtained wide recognition in the international world of cardiology and are considered a methodological landmark"<ref name="GISSI"/>. Four large-scale clinical trials over the past 20 years (GISSI 1<ref>{{cite journal |author= |title=Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) |journal=Lancet |volume=1 |issue=8478 |pages=397–402 |year=1986 |pmid=2868337 |doi=}}</ref><ref>{{cite journal |author= |title=Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI) |journal=Lancet |volume=2 |issue=8564 |pages=871–4 |year=1987 |pmid=2889079 |doi=}}</ref>, GISSI 2<ref>{{cite journal |author= |title=GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico |journal=Lancet |volume=336 |issue=8707 |pages=65–71 |year=1990 |pmid=1975321 |doi=}}</ref><ref>{{cite journal |author= |title=In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group |journal=Lancet |volume=336 |issue=8707 |pages=71–5 |year=1990 |pmid=1975322 |doi=}}</ref>, GISSI 3<ref>{{cite journal |author= |title=GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico |journal=Lancet |volume=343 |issue=8906 |pages=1115–22 |year=1994 |pmid=7910229 |doi=}}</ref>, GISSI Prevention<ref>{{cite journal |author= |title=Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico |journal=Lancet |volume=354 |issue=9177 |pages=447–55 |year=1999 |pmid=10465168 |doi=}}</ref>) have involved more than 60,000 patients with acute [[myocardial infarction]] ([[AMI]]).<ref name="GISSI"/>
The '''Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico''' (GISSI) (Italian group for the study of the survival of Myocardial Infarction) is an influential [[cardiology]] research group founded as a collaboration between two Italian organisations – the Mario Negri Institute and the Associazione Nazionale dei Medici Cardiologi Ospedalieri (ANMCO).<ref name="GISSI">http://www.gissi.org/EngIntro/T_Intro_ENG.php</ref> The trials carried out by GISSI have "obtained wide recognition in the international world of cardiology and are considered a methodological landmark"<ref name="GISSI"/>. Four large-scale clinical trials over the past 20 years (GISSI 1<ref>{{cite journal |author= |title=Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) |journal=Lancet |volume=1 |issue=8478 |pages=397–402 |year=1986 |pmid=2868337 |doi=}}</ref><ref>{{cite journal |author= |title=Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI) |journal=Lancet |volume=2 |issue=8564 |pages=871–4 |year=1987 |pmid=2889079 |doi=}}</ref>, GISSI 2<ref>{{cite journal |author= |title=GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico |journal=Lancet |volume=336 |issue=8707 |pages=65–71 |year=1990 |pmid=1975321 |doi=}}</ref><ref>{{cite journal |author= |title=In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group |journal=Lancet |volume=336 |issue=8707 |pages=71–5 |year=1990 |pmid=1975322 |doi=}}</ref>, GISSI 3<ref>{{cite journal |author= |title=GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico |journal=Lancet |volume=343 |issue=8906 |pages=1115–22 |year=1994 |pmid=7910229 |doi=}}</ref>, GISSI Prevention<ref>{{cite journal |author= |title=Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico |journal=Lancet |volume=354 |issue=9177 |pages=447–55 |year=1999 |pmid=10465168 |doi=}}</ref>) have involved more than 60,000 patients with acute [[myocardial infarction]] ([[AMI]]).<ref name="GISSI"/>
Line 10: Line 10:
*[http://www.olivehealth.com/articles/olive-oil-health-effects/olive-oil-and-heart-disease.html Article on olive oil and heart disease] - mentions the GSSI Prevention study
*[http://www.olivehealth.com/articles/olive-oil-health-effects/olive-oil-and-heart-disease.html Article on olive oil and heart disease] - mentions the GSSI Prevention study


{{SIB}}
 
[[Category: Research groups]]
[[Category: Medical research]]
[[Category: Research]]


{{WH}}
{{WH}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 02:56, 9 August 2012

WikiDoc Resources for GISSI

Articles

Most recent articles on GISSI

Most cited articles on GISSI

Review articles on GISSI

Articles on GISSI in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on GISSI

Images of GISSI

Photos of GISSI

Podcasts & MP3s on GISSI

Videos on GISSI

Evidence Based Medicine

Cochrane Collaboration on GISSI

Bandolier on GISSI

TRIP on GISSI

Clinical Trials

Ongoing Trials on GISSI at Clinical Trials.gov

Trial results on GISSI

Clinical Trials on GISSI at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on GISSI

NICE Guidance on GISSI

NHS PRODIGY Guidance

FDA on GISSI

CDC on GISSI

Books

Books on GISSI

News

GISSI in the news

Be alerted to news on GISSI

News trends on GISSI

Commentary

Blogs on GISSI

Definitions

Definitions of GISSI

Patient Resources / Community

Patient resources on GISSI

Discussion groups on GISSI

Patient Handouts on GISSI

Directions to Hospitals Treating GISSI

Risk calculators and risk factors for GISSI

Healthcare Provider Resources

Symptoms of GISSI

Causes & Risk Factors for GISSI

Diagnostic studies for GISSI

Treatment of GISSI

Continuing Medical Education (CME)

CME Programs on GISSI

International

GISSI en Espanol

GISSI en Francais

Business

GISSI in the Marketplace

Patents on GISSI

Experimental / Informatics

List of terms related to GISSI


The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) (Italian group for the study of the survival of Myocardial Infarction) is an influential cardiology research group founded as a collaboration between two Italian organisations – the Mario Negri Institute and the Associazione Nazionale dei Medici Cardiologi Ospedalieri (ANMCO).[1] The trials carried out by GISSI have "obtained wide recognition in the international world of cardiology and are considered a methodological landmark"[1]. Four large-scale clinical trials over the past 20 years (GISSI 1[2][3], GISSI 2[4][5], GISSI 3[6], GISSI Prevention[7]) have involved more than 60,000 patients with acute myocardial infarction (AMI).[1]

References

  1. 1.0 1.1 1.2 http://www.gissi.org/EngIntro/T_Intro_ENG.php
  2. "Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)". Lancet. 1 (8478): 397–402. 1986. PMID 2868337.
  3. "Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI)". Lancet. 2 (8564): 871–4. 1987. PMID 2889079.
  4. "GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico". Lancet. 336 (8707): 65–71. 1990. PMID 1975321.
  5. "In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group". Lancet. 336 (8707): 71–5. 1990. PMID 1975322.
  6. "GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico". Lancet. 343 (8906): 1115–22. 1994. PMID 7910229.
  7. "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico". Lancet. 354 (9177): 447–55. 1999. PMID 10465168.

Further reading

Template:WH Template:WikiDoc Sources